^
Association details:
| Biomarker: | SMARCB1 A240fsX28 |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.
Published date:
05/19/2021
Excerpt:
Table summarizes matched therapies in responders....Sarcoma...SMARCB1: A240fs*28...Palbociclib – SD, 6 mo...Tazemetostat – SD, 2 yrs
DOI:
10.1200/JCO.2021.39.15_suppl.11538
